Clinical Trial Update: Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma [NA]

View source ↗

Summary

This clinical trial update reports an ongoing study evaluating a three-drug regimen (pomalidomide plus orelabrutinib and zuberitamab) in untreated mantle cell l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Pomalyst (pomalidomide)
• Zuberitamab (Zuberitamab)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Mantle Cell Lymphoma (MCL), POZ | NA | Status: RECRUITING